Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

Welcome to Campus Sanofi Kuwait

Access all the content and events you need to continue growing as a health professional.

Create an account Login
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Asthma
Asthma
Atopic Dermatitis
Atopic Dermatitis
Cardiovascular
Cardiovascular
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Diabetes
Diabetes
Eosinophilic Esophagitis
Eosinophilic Esophagitis
Multiple Sclerosis
Multiple Sclerosis
Nasal Polyps
Nasal Polyps
Multiple Myeloma
Multiple Myeloma
Prurigo Nodularis
Prurigo Nodularis
Rare Diseases
Rare Diseases
Transplant
Transplant
Vaccines
Vaccines

Latest trends

Explore the most popular scientific articles and videos among Campus Sanofi users

Implementing Beyfortus successfully

Implementing Beyfortus successfully

Learn more
Beyfortus in Action ECMMID

Beyfortus in Action ECMMID

Learn more
2024 RSV International Congress ECMMID

2024 RSV International Congress ECMMID

Learn more
Beyfortus®, an innovative immunization

Beyfortus®, an innovative immunization

Learn more
Implementing Beyfortus successfully (ES)

Implementing Beyfortus successfully (ES)

Learn more
Implementing Beyfortus successfully (FR)

Implementing Beyfortus successfully (FR)

Learn more
Beyfortus in Action

Beyfortus in Action

Learn more
Implementing Beyfortus successfully (US)

Implementing Beyfortus successfully (US)

Learn more

Events

Stay up to date and register for the latest events and view webinar recordings

Dia-Tour: Navigating New Destinations in Diabetes Management

Dia-Tour: Navigating New Destinations in Diabetes Management

Learn more
Fabry Monitoring Matters Webinar Series

Fabry Monitoring Matters Webinar Series

Learn more
World Diabetes Day

World Diabetes Day

Learn more
Safe & Smart - Dr. Salah

Safe & Smart - Dr. Salah

Learn more
Diatour Inquiry Form

Diatour Inquiry Form

Learn more
5th Rare Disease Academy

5th Rare Disease Academy

Learn more
Sir Robin Murray updates us on Schizophrenia and it’s treatments

Sir Robin Murray updates us on Schizophrenia and it’s treatments

Updates on the Causes and Treatments of Schizophrenia

Learn more
Soliqua and Unmet Needs Webinar Summary

Soliqua and Unmet Needs Webinar Summary

Learn more

Support for your patients

Discover the selection of support materials for patients from different therapeutic areas

Are You Ready for 146? Achieving Optimal LDL-C Levels

Are You Ready for 146? Achieving Optimal LDL-C Levels

Learn more
Are You Ready for 556? Achieving Critical LDL-C Targets

Are You Ready for 556? Achieving Critical LDL-C Targets

Learn more
Exploring the 556/146 Concept: Insights from Leading Experts

Exploring the 556/146 Concept: Insights from Leading Experts

Learn more
Understanding the 556/146 Concept: Insights from Leading Experts

Understanding the 556/146 Concept: Insights from Leading Experts

Learn more
556/146 for Lipid Management after ACS

556/146 for Lipid Management after ACS

Learn more
Why Praluent is the Optimal Choice for Post-ACS Patients?
  • Dyslipidemia

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Learn more
How to Inject Praluent Once-Monthly 300 mg Pen?
  • Dyslipidemia

How to Inject Praluent Once-Monthly 300 mg Pen?

Learn more
How to Inject Praluent 75/150 mg Pen?
  • Dyslipidemia

How to Inject Praluent 75/150 mg Pen?

Learn more

Sanofi in News

Discover the selection of support materials for patients from different therapeutic areas

Ministry of Health organizes

Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools

Learn more
Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom

Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom

Learn more

Our Products

Aubagio®

AUBAGIO® is a once-daily oral tablet that is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS)

MAT-BH-2200903/V1/Nov2022

Clexane®

Enoxaparin Sodium is a low molecular weight heparin (LMWH) that is administered subcutaneously and used as antithrombotic agent.

MAT-BH-2400223/V2/JUL2024

Lemtrada®

Lemtrada® is a monoclonal antibody produced in mammalian cells (Chinese Hamster Ovary).

MAT-KW-2200058-V1-03/22

Plavix®

Clopidogrel is an inhibitor of platelet aggregation administered orally and indicated for Secondary prevention of atherothrombotic events.

MAT-BH-2100412/v2/Jul 2023

Renvela®

Sevelamer Carbonate is indicated for the control of hyperphosphatemia in adult patients receiving haemodialysis or peritoneal dialysis. The recommended starting dose of sevelamer carbonate is 2.4 g or 4.8 g per day and must be taken 3 times per day with meals.

MAT-BH-2300522/V1/October 2023

Tavanic®

Levofloxacin is used in adults for the treatment of infections. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.

MAT-BH-2200538/V1/August 2022

Zympass®

Combination of Rosuvastatin Calcium & Ezetimibe used as adjunct to diet for treatment of Primary Hypercholesterolemia or Homozygous Familial Hypercholesterolemia.

MAT-AE-2100356/v2/Oct 2022

This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.